Cargando…

Pathogenic Loss-of-Function Germline TERT Mutations in Patients With Solid Tumors

Detalles Bibliográficos
Autores principales:	Walsh, Michael F., Sacca, Rosalba, Wildman, Temima, Amoroso, Kimberly, Kennedy, Jennifer, Zhang, Liying, Birsoy, Ozge, Mandelker, Diana, Steinsnyder, Zoe, Latham, Alicia, Carlo, Maria I., Cadoo, Karen, Kemel, Yelena, Robson, Mark, Stadler, Zsofia K., Offit, Kenneth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2019
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446479/ https://www.ncbi.nlm.nih.gov/pubmed/32923861 http://dx.doi.org/10.1200/PO.19.00230

Ejemplares similares

Towards Automation of Germline Variant Curation in Clinical Cancer Genetics
por: Ravichandran, Vignesh, et al.
Publicado: (2019)

Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination
por: Setton, Jeremy, et al.
Publicado: (2021)

Germline SDHA mutations in children and adults with cancer
por: Dubard Gault, Marianne, et al.
Publicado: (2018)

NBN Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and In Vitro DNA Damage Response Defects
por: Belhadj, Sami, et al.
Publicado: (2023)

Fumarate hydratase c.914T > C (p.Phe305Ser) is a pathogenic variant associated with hereditary leiomyomatosis and renal cell cancer syndrome
por: Breen, Kelsey E., et al.
Publicado: (2020)

The context-specific role of germline pathogenicity in tumorigenesis
por: Srinivasan, Preethi, et al.
Publicado: (2021)

Expanded genetic testing of GIST patients identifies high proportion of non-syndromic patients with germline alterations
por: Mandelker, Diana, et al.
Publicado: (2023)

ATM Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications
por: El Jabbour, Tony, et al.
Publicado: (2022)

Diagnostic yield and clinical relevance of expanded genetic testing for cancer patients
por: Ceyhan-Birsoy, Ozge, et al.
Publicado: (2022)

A Clinical Approach to Detecting Germline Pathogenic Variants From Tumor-Only Sequencing
por: Ceyhan-Birsoy, PhD, Ozge, et al.
Publicado: (2020)

Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non–Muscle-Invasive Bladder Cancer
por: Pietzak, Eugene J., et al.
Publicado: (2022)

Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing
por: Terraf, P., et al.
Publicado: (2022)

Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer
por: Ku, Geoffrey Y., et al.
Publicado: (2021)

Methylation Analyses Reveal Promoter Hypermethylation as a Rare Cause of “Second Hit” in Germline BRCA1-Associated Pancreatic Ductal Adenocarcinoma
por: Zheng-Lin, Binbin, et al.
Publicado: (2022)

The Landscape of Somatic Genetic Alterations in Breast Cancers from CHEK2 Germline Mutation Carriers
por: Mandelker, Diana, et al.
Publicado: (2019)

Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies
por: Murciano-Goroff, Yonina R., et al.
Publicado: (2022)

Cascading After Peridiagnostic Cancer Genetic Testing: An Alternative to Population-Based Screening
por: Offit, Kenneth, et al.
Publicado: (2020)

Development of a novel measure of advanced cancer patients’ perceived utility of secondary germline findings from tumor genomic profiling
por: Hamilton, Jada G., et al.
Publicado: (2023)

Germline TERT promoter mutations are rare in familial melanoma
por: Harland, Mark, et al.
Publicado: (2015)

11p15.5 epimutations in children with Wilms tumor and hepatoblastoma detected in peripheral blood
por: Fiala, Elise M., et al.
Publicado: (2020)

Germline BRCA2 mutations detected in pediatric sequencing studies impact parents’ evaluation and care
por: Walsh, Michael F., et al.
Publicado: (2017)

Activating somatic and germline TERT promoter variants in myeloid malignancies
por: Nofrini, Valeria, et al.
Publicado: (2020)

The TERT promoter mutation incidence is modified by germline TERT rs2736098 and rs2736100 polymorphisms in hepatocellular carcinoma
por: Yuan, Xiaotian, et al.
Publicado: (2017)

The germline sequence variant rs2736100_C in TERT associates with myeloproliferative neoplasms
por: Oddsson, A, et al.
Publicado: (2014)

Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms
por: Jäger, Roland, et al.
Publicado: (2014)

Characterization of a germline variant MSH6 c.4001G > C in a Lynch syndrome family
por: Yang, Ciyu, et al.
Publicado: (2023)

Germline ETV6 Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia
por: Topka, Sabine, et al.
Publicado: (2015)

Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing
por: Balmaña, Judith, et al.
Publicado: (2016)

A Germline Variant on Chromosome 4q31.1 Associates with Susceptibility to Developing Colon Cancer Metastasis
por: Markowitz, Sanford D., et al.
Publicado: (2016)

Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing
por: Cheng, Donavan T., et al.
Publicado: (2017)

Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer
por: Hamilton, Jada G., et al.
Publicado: (2021)

Germline variations at JAK2, TERT, HBS1L-MYB and MECOM and the risk of myeloproliferative neoplasms in Taiwanese population
por: Chiang, Yi-Hao, et al.
Publicado: (2017)

Papillary Thyroid Cancer and a TERT Promotor Mutation-positive Paraganglioma in a Patient With a Germline SDHB Mutation
por: Alzahrani, Ali S, et al.
Publicado: (2022)

TERT Extra-Telomeric Roles: Antioxidant Activity and Mitochondrial Protection
por: Marinaccio, Jessica, et al.
Publicado: (2023)

TERT promoter mutations and monoallelic activation of TERT in cancer
por: Huang, F W, et al.
Publicado: (2015)

Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer
por: Navitski, Anastasia, et al.
Publicado: (2021)

Di-tert-butyl N-[2,6-bis(methoxymethoxy)phenyl]iminodiacetate
por: Capuano, Ben, et al.
Publicado: (2009)

Evaluating the role of aromatase inhibitors in the treatment of low-grade endometrial stromal sarcomas
por: Crowley, Fionnuala, et al.
Publicado: (2022)

(R)-N-{2-tert-Butyl-2-[(R)-tert-butylsulfonamido]ethylidene}-tert-butanesulfonamide
por: Hu, Yu, et al.
Publicado: (2008)

Elevated TERT Expression in TERT-Wildtype Adult Diffuse Gliomas: Histological Evaluation with a Novel TERT-Specific Antibody
por: Masui, Kenta, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_k31orod0ep51due8borqc0i156